European Commission Approves Eisai-Biogen's Leqembi For Early Alzheimer's Disease Treatment
16/4 03:12
(RTTNews) - Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced that the European Commission has granted the amyloid-beta (A) monoclonal antibody Leqembi (lecanemab) Marketing Authorization in the European Union....